Protein hydrolysate/leucine co-ingestion reduces the prevalence of hyperglycemia in type 2 diabetic patients

Diabetes Care. 2006 Dec;29(12):2721-2. doi: 10.2337/dc06-1424.

Authors

Ralph J F Manders¹, Stephan F E Praet, Ruth C R Meex, René Koopman, André L de Roos, Anton J M Wagenmakers, Wim H M Saris, Luc J C van Loon

Affiliation

¹ Department of Human Biology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, Netherlands. r.manders@hb.unimaas.nl

PMID: 17130211
DOI: 10.2337/dc06-1424

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Adult
Blood Glucose / drug effects
Blood Glucose / metabolism
Circadian Rhythm
Diabetes Mellitus, Type 2 / blood*
Humans
Hyperglycemia / epidemiology*
Hyperglycemia / prevention & control*
Leucine / administration & dosage
Leucine / therapeutic use*
Prevalence
Protein Hydrolysates / administration & dosage
Protein Hydrolysates / therapeutic use*
Reference Values

Substances

Blood Glucose
Protein Hydrolysates
Leucine